Finance

Lists
GMAB:NASDAQ
Genmab A/S - ADR
US$ ५१.३५
+०.७५%
(+०.३८) 1D
US$ ५१.३५
०.००% (०.००)
After hours
Closed: नोभेम्बर १९, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GMAB...
Open
US$ ५१.५४
High
US$ ५२.४०
Low
US$ ५०.९४
Mkt. cap
३२.४४ अरब
Avg. vol.
५४.३३ लाख
Volume
३८.१३ लाख
P/E ratio
४३.७३
52-wk high
US$ ५९.९७
52-wk low
US$ २३.६२
EPS
US$ १.१७
Beta
०.७३
Shares outstanding
६२.५७ करोड
No. of employees
३ हजार
Open
US$ ५१.५४
High
US$ ५२.४०
Low
US$ ५०.९४
Mkt. cap
३२.४४ अरब
Avg. vol.
५४.३३ लाख
Volume
३८.१३ लाख
P/E ratio
४३.७३
52-wk high
US$ ५९.९७
52-wk low
US$ २३.६२
EPS
US$ १.१७
Beta
०.७३
Shares outstanding
६२.५७ करोड
No. of employees
३ हजार
News stories
From web sources and news partners
Investing.com
Investing.com
·
९ घण्टा पहिले
Genmab at Jefferies Global Healthcare Conference: pipeline turns
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S - ADR
CEOJan G. J. van de Winkel
Employees३.२४ हजार
Founded१९९९
Headquarters-
SectorHealth Care
Industry-
Websitegenmab.com
Analyst ratings
Based on 9 analysts giving stock ratings to GMAB in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for GMAB in the last 3 months.
Highest
Current US$ ५१.३५
US$ ८०.०० (+५५.७९%)
Average
US$ ६४.५७ (+२५.७४%)
Lowest
US$ ५२.०० (+१.२७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Hold
Maintained
US$ ५६.००
+९.१%
11/13/2026
Charlie Haywood
Bank of America Securities
Buy
Maintained
-
-
11/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$ ७०.००
+३६.३%
11/06/2026
Gregory Renza
Truist Financial
Buy
Maintained
US$ ६७.००
+३०.५%
11/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
US$ ८०.००
+५५.८%
10/29/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
US$ ५७.००
+११%
10/30/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
US$ ६२.००
+२०.७%
10/29/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
US$ ६२.००
+२०.७%
10/29/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
10/29/2026
Asthika Goonewardene
Leerink Partners
Buy
Reiterated
US$ ६५.००
+२६.६%
10/29/2026
Yaron Werber
TD Cowen
Buy
Reiterated
US$ ५२.००
+१.३%
10/26/2026
Benjamin Jackson CFA
Jefferies
Buy
Maintained
-
-
08/07/2026
James Gordon CFA
Barclays
Buy
Maintained
-
-
08/07/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
US$ ४०.००
-२२.१%
06/29/2026
Kalpit Patel
Wolfe Research
Buy
Maintained
US$ ३२.००
-३७.७%
06/14/2026
Last report
२०२६ नोभेम्बर ५
Fiscal period
Q3 2026
DKK ३७.५३ / DKK २२.९४
+६३.५९%beat
Revenue / Est. (DKK)
७.९१ अरब / ८.०६ अरब
-१.८८%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
२०२३ डिसेम्बर
२०२४ मार्च
२०२४ जुन
२०२४ सेप्टेम्बर
Revenue
४.६८ अरब
४.१४ अरब
५.४० अरब
५.५४ अरब
Cost of goods sold
-
-
-
२७.३० करोड
Cost of revenue
-
-
-
२७.३० करोड
Research and development expenses
-
-
-
२.२८ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
८६.५० करोड
Operating expense
-
-
-
३.१५ अरब
Total operating expenses
-
-
-
३.४२ अरब
Operating income
-
-
-
२.१२ अरब
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
१.७२ अरब
EBT excluding unusual items
-
-
-
१.५९ अरब
Income tax expense
-
-
-
४५.३० करोड
Effective tax rate
-
-
-
२६.३५%
Other operating expenses
-
-
-
-
Net income
-
-
-
१.२७ अरब
Net profit margin
-
-
-
२२.८५%
Earnings per share
९.६७
-
-
१९.८१
Interest and investment income
-
-
-
१६.२० करोड
Interest expense
-
-
-
-१.८० करोड
Net interest expenses
-
-
-
१४.४० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
२.२० अरब
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू